HWAM
ATRA icon

Hennion & Walsh Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,762
Closed -$82.6K – 843
2024
Q1 		$82.6K Buy
4,762
+317
+7% +$5.63K ﹤0.01% 836
2023
Q4 		$57K Sell
4,445
-2,312
-34% -$53.9K ﹤0.01% 815
2023
Q3 		$250K Sell
6,757
-408
-6% -$18.2K 0.02% 695
2023
Q2 		$288K Sell
7,165
-3,601
-33% -$204K 0.02% 660
2023
Q1 		$781K Sell
10,766
-322
-3% -$31.2K 0.05% 409
2022
Q4 		$909K Buy
11,088
+1,233
+13% +$128K 0.06% 364
2022
Q3 		$931K Buy
9,855
+714
+8% +$80.2K 0.06% 341
2022
Q2 		$1.78M Buy
9,141
+2,879
+46% +$470K 0.11% 217
2022
Q1 		$1.45M Buy
6,262
+1,242
+25% +$395K 0.08% 270
2021
Q4 		$1.98M Buy
5,020
+2,002
+66% +$843K 0.1% 236
2021
Q3 		$1.35M Buy
3,018
+1,033
+52% +$370K 0.07% 295
2021
Q2 		$772K Buy
1,985
+967
+95% +$345K 0.04% 419
2021
Q1 		$366K Buy
+1,018
New +$450K 0.02% 553

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Hennion & Walsh Asset Management's ATRA Position: Q2 2024 in Review

Hennion & Walsh Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 4,762 shares — an estimated $82.6K sold.

Hennion & Walsh Asset Management first reported a position in ATRA in Q1 2021 and held it in 13 quarters. The position peaked at $1.98M in Q4 2021. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Hennion & Walsh Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 4,762 Atara Biotherapeutics shares in Q2 2024, an estimated $82.6K.
  • Hennion & Walsh Asset Management first reported a position in Atara Biotherapeutics in Q1 2021 and held it in 13 quarters.
  • Hennion & Walsh Asset Management's Atara Biotherapeutics position peaked at $1.98M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2024, filed 19 Jul 2024.